Background: Fabry disease is associated with cardiomyopathy, early-onset stroke, and progressive renal failure, and other features. No markers predict multisystemic disease progression. The hypothesis of the current study is to assess a clinically relevant marker for Fabry disease using polymorphic genotyping of a marker that has been shown to be involved in interrelated cardiac, vascular, and renal abnormalities in patients not affected by Fabry disease. The paraoxonase (PON1) polymorphisms, Leu55Met and Gln192Arg, modulate intima-medial artery thickening, prognosis of cardiovascular stroke, and renal failure in other diseases. Methods: PON1 polymorphisms were ascertained. The Mainz Severity Score Index (MSSI) for Fabry disease was calculated. Local Institutional Review Board approval was received. Results: 104 patients (58 female) and 46 controls (23 female) were evaluated. There was a significant difference (p = 0.04) in PON55LL (42.3%) among patients as compared to controls (21.7%) but none in PON192 genotypes. PON55 variant (MM) was correlated with severe MSSI renal sub-scores (p < 0.001) also when age-adjusted but not with cardiac, neurological, or general sub-scores. PON55LL genotype, correlated with higher PON1 activity, had lowest α-galactosidase-A activity (n = 45). Conclusion: There was no combined effect of PON55-PON192 polymorphisms. PON55LL was more common among patients. PON55MM genotype was correlated with non-mild renal sub-scores. However, sample size needs to be enlarged.

Keywords:
Fabry disease, Paraoxonase, Polymorphisms, Renal disease, Severity score
1.
Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163–1167.
2.
Mehta A, Ricci R, Widmer U, et al: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236–242.
3.
Altarescu G, Elstein D: Cardiac abnormalities in Fabry disease: natural history in hemizygote males suggests that cardiac pathology is universally present. Haema 2004;8:103–108.
4.
Moore DF, Kaneski CR, Askari H, Schiffmann R: The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258–263.
5.
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539–548.
6.
Kalliokoski RJ, Kalliokoski KK, Penttinen M, Kantola I, Leino A, Viikari JS, Simell O, Nuutila P, Raitakari OT: Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis 2006;29:660–666.
7.
Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C; Fabry Registry: Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008;23:1600–1607.
8.
Altarescu G, Moore D, Schiffmann R: Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005;64:2148–2150.
9.
Safyan R, Whybra C, Beck M, Elstein D, Altarescu G: An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw 2006;17:271–275.
10.
Martinelli N, Girelli D, Olivieri O, Cavallari U, Biscuola M, Trabetti E, Friso S, Pizzolo F, Tenuti I, Bozzini C, Villa G, Ceradini B, Sandri M, Cheng S, Grow MA, Pignatti PF, Corrocher R: Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease. Clin Exp Med 2005;5:20–30.
11.
Gullulu M, Kahvecioglu S, Dirican M, Akdag I, Ocak N, Demircan C, Dilek K, Ersoy A, Yavuz M, Yurtkuran M: Paraoxonase activity in glomerulonephritic patients. Ren Fail 2007;29:433–439.
12.
Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL: Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265–1276.
13.
Najafi M, Firoozrai M, Gohari HL, Zavarehie A, Basiri G: Direct haplotyping of bi-allelic SNPs using ARMS and RFLP analysis techniques. Biomol Eng 2007;24:609–612.
14.
Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M: The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299.
15.
Poulakou MV, Paraskevas KI, Vlachos IS, Karabina SA, Wilson MR, Iliopoulos DC, Tsitsilonis SI, Mikhailidis DP, Perrea DN: Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology 2008;59:137–144.
16.
Ferretti G, Bacchetti T, Masciangelo S, Nanetti L, Mazzanti L, Silvestrini M, Bartolini M, Provinciali L: Lipid peroxidation in stroke patients. Clin Chem Lab Med 2008;46:113–117.
17.
Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, Arii K, Hashimoto K: Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007;67:358–365.
18.
Harangi M, Seres I, Magyar MT, Csipo I, Sipka S, Valikovics A, Csiba L, Bereczki D, Paragh G: Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc Dis 2008;25:122–128.
19.
Thyagarajan B, Jacobs DR Jr, Carr JJ, Alozie O, Steffes MW, Kailash P, Hayes JH, Gross MD: Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2008;54:738–746.
20.
Schiavon R, Turazzini M, De Fanti E, Battaglia P, Targa L, Del Colle R, Fasolin A, Silvestri M, Biasioli S, Guidi G: PON1 activity and genotype in patients with arterial ischemic stroke and in healthy individuals. Acta Neurol Scand 2007;116:26–30.
21.
Can Demirdöğen B, Türkanoğlu A, Bek S, Sanisoğlu Y, Demirkaya S, Vural O, Arinç E, Adali O: Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008;41:1–9.
22.
Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P, Kao A, Bontempo F, Kammerer C, Kamboh MI: Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006;54:1928–1939.
23.
Kovács TJ, Harris S, Vas TK, Seres I, Short CD, Wittmann IK, Paragh G, Mackness MI, Mackness B, Durrington PN, Nagy JM, Brenchley PE: Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy. J Nephrol 2006;19:732–738.
24.
Garcés C, López-Simón L, Rubio R, Benavente M, Cano B, Ortega H, de Oya M: High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain. Clin Chem Lab Med 2008;46:809–813.
25.
Sanghera DK, Manzi S, Minster RL, Shaw P, Kao A, Bontempo F, Kamboh MI: Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann Hum Genet 2008;72:72–81.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.